Accessibility Menu
Telix Pharmaceuticals logo

Telix Pharmaceuticals(NASDAQ) TLX

Market Cap$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-33%
5 YearN/A
1 Year-30%
1 Month-6%
$9.96
-2.54%
-0.26Today
Telix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 9.982026-07-27
Telix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.04%USD 10.512026-07-20
1 month-6.38%USD 10.662026-06-26
3 month-4.41%USD 10.442026-04-28
Year to date+33.24%USD 7.492025-12-31
1 year-29.72%USD 14.202025-07-25
Since inception-32.54%USD 15.152024-11-14

Telix Pharmaceuticals Financials at a Glance

Market Cap

$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.00B

Net Income (TTM)

A$39.18M

EPS (TTM)

-$0.02

P/E Ratio

-472.99

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$9.96

Volume

1,731

Open

$10.20

Previous Close

$9.96

Daily Range

$9.92 - $10.20

52-Week Range

$6.28 - $14.27

Estimated Earnings Date

Aug 20, 2026

TLX News

Adaptimmunenew

1 Basically Unknown Stock That Could Turn Cancer‑Imaging Breakthroughs Into Generational Wealth

James HalleyFeb 26, 2026

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, with a strong emphasis on innovative cancer treatments.

Products and Services
  • TLX591, a lutetium-labeled radio antibody-drug conjugate for advanced prostate cancer
  • TLX250, an rADC targeting advanced metastatic kidney cancer
  • Illuccix and Gozellix, products for prostate cancer treatment
Growth Outlook
  • Recent quarterly revenue reached AUD 620 million, indicating strong market demand
  • Ongoing Phase 3 trials for TLX591 and TLX250 could lead to significant product approvals
  • Expansion into international markets enhances growth potential and revenue streams
Financial Highlights
  • Trailing twelve months (TTM) revenue of AUD 2.4 billion reflects robust sales growth
  • Net income for the latest quarter was AUD -7.25 million, showing investment in R&D
  • Cash and cash equivalents stood at AUD 212 million, providing liquidity for operations
Telix Pharmaceuticals Limited is positioned in the biotechnology sector, focusing on innovative solutions for cancer treatment. The company's lead product candidates are in advanced clinical stages, which could significantly impact future revenue. The recent financial performance indicates a commitment to research and development, essential for long-term growth. With a solid cash position, Telix is well-equipped to navigate the complexities of the biopharmaceutical landscape while pursuing strategic collaborations and expanding its market presence.
AI Generated • Jul 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,184

CEO

Christian P. Behrenbruch, PhD, EMBA

Website

www.telixpharma.com

Headquarters

North Melbourne, VIC 3051, AU

TLX Financials

Key Financial Metrics (TTM)

Gross Margin

50.76%

Operating Margin

2.11%

Net Income Margin

-0.89%

Return on Equity

-1.72%

Return on Capital

2.02%

Return on Assets

-0.61%

Earnings Yield

-0.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

339.78M

Volume

1.73K

Avg. Volume

164.97K

Financials (TTM)

Gross Profit

A$1.13B

Operating Income

A$107.74M

EBITDA

A$160.90M

Operating Cash Flow

A$13.35M

Capital Expenditure

-A$64.41M

Free Cash Flow

-A$51.07M

Cash & ST Invst.

A$212.53M

Total Debt

A$699.77M

Telix Pharmaceuticals Performance Analysis

Telix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31AUD 110,983,5751846.6%
20232023-12-31AUD 333,573,719200.6%
20242024-12-31AUD 516,602,59754.9%
20252025-12-31AUD 804,636,84755.8%
Telix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-32.9%
Q42024-12-31214.5%
Q22025-06-30-0.2%
Q42025-12-314.6%
Telix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31AUD -0.238.5%
20232023-12-31AUD 0.01N/A
20242024-12-31AUD 0.10791.6%
20252025-12-31AUD -0.02N/A
Telix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-44.8%
Q42024-12-31230.3%
Q22025-06-30-109.4%
Q42025-12-31-107.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

A$620.44M

+120.2%

Gross Profit

A$327.42M

+46.2%

Gross Margin

52.77%

N/A

Market Cap

$3.39BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.99M

N/A

Employees

1,136

N/A

Net Income

-A$7.25M

-137.1%

EBITDA

A$28.92M

+25.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

A$212.53M

+72.5%

Total Debt

A$699.77M

+3911.3%

Accounts Receivable

A$207.29M

+220.0%

Inventory

A$55.55M

+220.9%

Long Term Debt

A$671.82M

+4129.0%

Short Term Debt

A$27.95M

+1692.9%

Return on Assets

-0.61%

N/A

Return on Invested Capital

1.81%

N/A

Free Cash Flow

-A$92.60M

-2441.3%

Operating Cash Flow

-A$52.55M

-594.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CELCCelcuity Inc.
$82.27-0.42%
SLNOSoleno Therapeutics, Inc.
$53.01+0.00%
RAREUltragenyx Pharmaceutical Inc.
$26.89-0.04%
DYNDyne Therapeutics, Inc.
$25.63+4.87%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%

Questions About TLX

What is the current price of Telix Pharmaceuticals?

Telix Pharmaceuticals is trading at $9.96 per share.

What is the 52-week range for Telix Pharmaceuticals?

Over the past 52 weeks, Telix Pharmaceuticals has traded between $6.28 and $14.27.

How much debt does Telix Pharmaceuticals have?

As of the most recent reporting period, Telix Pharmaceuticals reported total debt of A$467.11M.

How much cash does Telix Pharmaceuticals have on hand?

Telix Pharmaceuticals reported A$141.87M in cash and cash equivalents in its most recent financial results.

What is Telix Pharmaceuticals’s dividend yield?

Telix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services